Caxton Corp Glycomimetics Inc Transaction History
Caxton Corp
- $15.8 Million
- Q4 2024
A detailed history of Caxton Corp transactions in Glycomimetics Inc stock. As of the latest transaction made, Caxton Corp holds 203,578 shares of GLYC stock, worth $59,037. This represents 0.32% of its overall portfolio holdings.
Number of Shares
203,578Holding current value
$59,037% of portfolio
0.32%Shares
5 transactions
Others Institutions Holding GLYC
# of Institutions
43Shares Held
30.3MCall Options Held
51KPut Options Held
1.4K-
Bvf Inc San Francisco, CA9.54MShares$2.77 Million0.09% of portfolio
-
Logos Global Management LP San Francisco, CA5.4MShares$1.57 Million0.18% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.09MShares$1.48 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3MShares$869,9990.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$774,3600.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $15.2M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...